Scotland’s health technology appraisal (HTA) body, the Scottish Medicines Consortium, has accepted Sanofi’s Dupixent (dupilumab) for treating prurigo nodularis, a rare and chronic skin condition, while England’s NICE has rejected the drug for this indication. Different approaches to comparators used in the studies supporting Sanofi’s submissions are one reason for the diverging decisions.
In February’s raft of recommendations on medicines to be accepted for use on the Scottish National Health Service, the SMC...








